Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (ECOR) is a leader in non-invasive vagus nerve stimulation therapies, providing innovative solutions for neurological conditions and wellness applications. This page serves as the definitive source for ECOR news, offering investors and professionals timely updates on regulatory developments, clinical research, and strategic initiatives.
Access curated press releases covering FDA clearances, partnership announcements, and financial results. Stay informed about advancements in gammaCore™ therapies for migraine treatment and TAC-STIM cognitive enhancement technologies. Our repository includes updates on international expansions, clinical trial outcomes, and product pipeline developments.
Bookmark this page for direct access to primary source materials from electroCore, including neuromodulation research breakthroughs and commercialization progress across healthcare and defense sectors. Regular updates ensure you maintain current awareness of ECOR's position in the evolving bioelectronic medicine landscape.
electroCore, Inc. (NASDAQ: ECOR) announced a public offering of 18 million shares at $1.00 each, raising approximately $18 million before expenses. The offering is expected to close around July 2, 2021. Underwriters have a 45-day option for an additional 2.7 million shares. Proceeds will support sales, marketing, working capital, and potential business expansions, although no specific acquisitions are currently planned. The offering is made under an effective shelf registration statement with the SEC.
electroCore, Inc. (NASDAQ: ECOR) announced a public offering of its common stock. The offering, which is subject to market conditions, aims to raise funds for sales, marketing, working capital, and potential acquisitions. The company will grant underwriters a 45-day option to purchase an additional 15% of shares. Ladenburg Thalmann & Co. Inc. is the sole book-runner, with Paulson Investment Company as co-manager. The offering will utilize an effective shelf registration statement filed with the SEC, and a preliminary prospectus will be available soon.
On June 10, 2021, electroCore, Inc. (Nasdaq: ECOR) announced the publication of a peer-reviewed study in Communications Biology highlighting the positive effects of non-invasive vagus nerve stimulation (nVNS) on cognitive performance in sleep-deprived Air Force personnel. The trial found that nVNS improved throughput capacity by 10% compared to a sham treatment, with lasting effects. This research opens avenues for nVNS in both military and civilian settings, addressing fatigue-related cognitive impairments. The findings suggest potential market growth for gammaCore's applications.
electroCore, Inc. (Nasdaq: ECOR) has partnered with Kromax International Corporation as the exclusive distributor of its gammaCore Sapphire™ non-invasive vagus nerve stimulator in Taiwan and China. This three-year agreement aims to enhance healthcare quality in pain management, particularly for migraine sufferers. The partnership is contingent on regulatory approvals, with the timing of these clearances currently uncertain. Both companies aim to improve patient outcomes through innovative healthcare solutions.
electroCore, a bioelectronic medicine company, will be added to the Russell Microcap Index effective June 28, 2021. This inclusion enhances the company's visibility to institutional investors and investment managers. The Russell Microcap Index tracks smaller market-cap companies and is part of FTSE Russell, which manages approximately $10.6 trillion in assets. CFO Brian Posner emphasized that being part of this index represents a significant opportunity for shareholder value.
electroCore, Inc. (Nasdaq: ECOR) has successfully sold $1.4 million in tax benefits through the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer program for fiscal years 2019 and 2020. This sale enhances the company's balance sheet and bolsters its cash position, aiding in the commercialization of gammaCore and expansion of its non-invasive vagus nerve stimulation therapy. The program allows eligible companies to convert net operating losses into cash, thus supporting their growth objectives.
electroCore, Inc. (NASDAQ: ECOR) announced a peer-reviewed publication demonstrating the efficacy of non-invasive vagus nerve stimulation (nVNS) for Parkinson's disease treatment. The randomized trial, conducted with 36 participants, indicated significant improvements in motor function, gait, and inflammation markers after nVNS. Enhanced walking speed and rhythm were observed, with minimal adverse events. The study highlights the potential for nVNS as an adjunctive therapy for Parkinson's patients. The findings emphasize the growing burden of Parkinson's disease, impacting over 1 million individuals in the U.S. with annual costs exceeding $51.9 billion.
electroCore, a bioelectronic medicine company listed on NASDAQ under the symbol ECOR, announced its participation in several investor conferences throughout June 2021. Key events include the Summer Solstice Best Ideas Conference on June 1 at 9:30 AM EDT, the LD Micro Invitational XI on June 8 at 3:30 PM EDT, and the JMP Securities Life Sciences Conference on June 17 at 12:30 PM EDT. CEO Dan Goldberger and CFO Brian Posner will present an overview of the company and conduct virtual meetings.
electroCore reported a strong first quarter in 2021, achieving net sales of $1.2 million, a 64% increase year-over-year and a 30% rise from the previous quarter. The company maintained a cash balance of $25.5 million as of March 31, 2021, with net cash used of $4.1 million. Significant achievements include obtaining a unique CMS reimbursement code and expanding gammaCore's FDA indication for adolescent migraine treatment. Despite ongoing challenges, electroCore expects to exceed $1.2 million in net revenue for Q2 2021.
electroCore, Inc. (Nasdaq: ECOR) has announced an investigator-initiated study by the U.S. Department of Veterans Affairs to evaluate the efficacy of gammaCore Sapphire™ for treating post-traumatic headache (PTH). The study targets 100 veterans and is led by the VA Headache Center of Excellence. PTH is common among veterans with traumatic brain injuries. With over 350,000 veterans affected, this study aims to expand gammaCore's application, previously successful in treating cluster headaches. The randomized trial highlights the commitment to improving veterans' healthcare outcomes.
